We have attempted to produce the 13%kDa early protein (ep138) of Epstein-Barr virus (EBV) in Escherichia coZi. This protein was found, by immunoprecipitation, to be a clinically relevant antigen, especially for the determination of the IgA-titer in patients with nasopharyngeal carcinoma (NPC). Since the expression of the entire ep138 coding region was unsuccessful, we synthesized only the antigenic parts of this protein. Potential antigenic sites were predicted from the amino acid sequence by combining values for hydrophilicity with calculated estimates of the secondary structure. The two predicted fragments were found to be antigenic, but only one of them was stably expressed in E. coli as a non-fusion protein. This stable protein fragment was, in turn, able to stabilize the second antigenic fragment forming an autologous fusion protein, consisting exclusively of EBV-derived sequences. The resulting product reacts particularly well with IgA antibodies of NPC patients indicating its diagnostic value for NPC.
INTRODUCTION
Epstein-Barr virus (EBV) can cause infectious mononucleosis after primary infection and is strongly linked to the undifferentiated form of NPC and as an etiologic factor to African Burkitt's lymphoma. In some areas of Southern China, Singapore and Malaysia, NPC is the most frequent neoplasia with an incidence of up to 40 cases per 100000 inhabitants per year. Early detection is particularly important because this tumor responds very well to radiotherapy in the early stages (survival rates up to 93% in stage I and 75 y0 in stage II) and dramatically less in Field studies have already demonstrated the value of serological screening (Zeng et al., 1985) . (For references on the EBV-related diseases and diagnosis see Simons and Shanmugaratnam, 1982.) Mass screening of the high-risk groups would be possible if inexpensive and automat-readable tests were available. When partially purified antigens from EBV-producing cell cultures are used, tests are prone to background reactions and are expensive. Therefore we decided to produce an EBV-related antigen by gene technological methods and use it in an ELISA. This should result in higher sensitivity and provide a low-cost, rapid screening system for the early detection of NPC and also for the diagnosis of other EBV-related diseases.
We describe approaches for the expression of ep 138, which belongs to the early antigen group in the lytic EBV infection. This protein is known to be a major DNA-binding protein which shares homologies to the ICP8 from HSVl (D. McGeoch, R.S. and H.W., unpublished).
We selected the ep138 for several reasons:
after induction of EBV-infected cells the ep138 is one of the most abundant early proteins (Bayliss and Wolf, 1981) ; sera from different NPC-patients contain antibodies against this protein (Wolf et al, 1984) ; the coding region was located in the BamHI-A fragment in an area with appropriate reading frames (Seibl and Wolf, 1985) . Yanisch-Perron, et al., 1985) and plasmids pUC8, pUC9, pUC13 (Vieira and Messing, 1982) , pEA305 (Amann et al., 1983 ), pKK240-11 (Amann and Brosius, 1985 ), pUR278, pUR288 (RUther and MUller-Hill, 1983 ) and pINIIIAl (Masui et al., 1984) were used.
(b) DNA-sequences and computer programs
The sequence of the BamHI-A fragment was obtained from B. Barrel1 (Baer et al., 1984) prior to publication. For searching restriction enzyme sites, reading frames and maps the UWGCG programs (Devereux et al., 1984) were used.
The program for the prediction of antigenic sites by calculating the secondary structures superimposed with values for hydrophilicity was developed in our laboratory for the VAX750 on the basis of a program written by E. Golub (Cohen et al., 1984) . Our program was written to function as a subprogram of the UWGCG software and can therefore directly use sequences from the major protein or nucleic acid libraries.
(c) Induction and analysis of expression products
Overnight cultures of clones containing the desired plasmids were grown in LB-medium containing 50 pg Ap/ml. They were diluted to an A = 0.3; when the A reached 0.7, IPTG was added to give a final concentration of 1 mM and the cultures were incubated for another 2 h. Cell pellets from 1.5 ml culture were lysed in 150 ~1 of sample buffer (Laemmli, 1970) , boiled for 5 min and lo-25 ~1 of the lysate were separated by SDS-PAGE and evaluated after staining with Coomassie blue.
(d) Detection of EBV-related antigenic proteins

MATERIALS AND METHODS
(a) Bacterial strains and plasmids
The BamHI-A fragment of EBV containing the region coding for ep138, cloned into the BamHI site of pBR322, was obtained from J. Skare (1980) . For cloning and expression procedures E. coli strain JM83 {ara, strA, ZucZAM15, ~80}, and JM109 (recA1, endA 1, gyrA96, thi, hsdR17, .supE44, relA 1, , [F', traD36, After SDS-PAGE the proteins of the bacterial lysates were transferred onto nitrocellulose (Burnette, 198 1). The nitrocellulose filter was preadsorbed for 2 h with a modified 5 x Denhardt's solution (Denhardt, 1966) supplemented with 0.1% Nonidet P-40, 1.5% bovine serum albumin, 170 mM borate, 150 mM NaCl, 0.25% gelatine and 0.04% NaN, (Cohen et al., 1984) and incubated overnight at room temperature with a 1 : 50 diluted high-titered NPC serum pool (EA 1 : 1200, VCA 1 : 6600) or individu-al sera which were previously preadsorbed with bacterial lysates. After washing with gelatine buffer (50 mM Tris. HCl, pH 7.5, 5 mM Na,. EDTA, 150 mM NaCl, 0.25% gelatine, 0.5% Triton X-100, 0.1% SDS) the bound antibodies were incubated with peroxidase-conjugated anti-human IgG or IgA rabbit antibodies (Dako) and stained with 0.0 1 y0 H,O, and 0.5 mg/ml diaminobenzidine (Sigma).
RESULTS AND DISCUSSION
(a) Localization of the ORF coding for ep138
According to the mapping data obtained by hybrid-selected translation of mRNA from induced P3HRl cells probed with cloned BamHI fragments, the coding region for the ep138 is located in the BamHI-A fragment at the right end of the viral genome (Seibl and Wolf, 1985) . Three leftward oriented large ORFs can be identified from the sequence data. Although splice events cannot be excluded, an ORF at the right end of the BumHI-A (BALF2 according to Baer et al., 1984) was the right size to encode the ep138. To test our assumption, we inserted a 3.0-kb XhoI fragment spanning this ORF into pUC8 and used the resulting plasmid, pUC635, as a probe for a hybrid-selected translation of mRNA from induced P3HRl cells. Fig. 1 gives an overview on the localization of epl38-encoding sequences used for the engineering to obtain pUC635 and other clones described in the following. Fig. 2 shows that ep138 is encoded by this ORF, with 1128 aa and a calculated M, of 123 027.
(b) Synthesis of large segments of ep138
We used the pUC plasmid vectors, which have previously been used to express eukaryotic proteins in E. coli (e.g., Guise et al., 1985) or vectors with tuc promoters (DeBoer et al., 1983) . In addition to pUC635 (also used for mapping), three other plasmids with large fragments of the ep138 coding region were derived (pUC924, pMF924 and pKK378; and of two other proteins, which belong to the VCA group (Bayliss and Wolf, 1981) . are indicated (sizes in kDa). To select mRNA, 8 pg of pUC635 was sheared by sonication and spotted to 5 x 5 mm nitrocellulose filter. After washing and baking at 80°C for 2 h, 100 pg RNA from induced P3HRl cells (induction of P3HRI with 40 ng/ml phorbol-12-myristate-13-acetate and 3 mM butyric acid for three days) was hybridized to the filter.
Bound mRNA was eluted by boiling, precipitated with ethanol and translated with a mRNA dependent rabbit reticulocyte lysate in the presence of [35S]methionine as described earlier (Seibl and Wolf, 1985) . For translation of unselected RNA, 7 ng were added to the translation assay. The labeled proteins were mixed with immunoprecipitation buffer (1 y0 Triton X-100,0.1 Y0 SDS, 0.137 M NaCl, 1 mM CaCI,, 1 mM MgCl,, 10'4 glycerol, All the expression-plasmid-produced segments of ep138 were in the expected M, range, but the yield was low and varied widely. The fusion proteins encoded by the constructs pUC635 and pMF924 seem to give better expression in a more stable fashion than the non-fusion proteins from pUC924 and pKK378. The antigen yield from pUC635, which gave the highest expression, was far too low for large-scale production. A reproducible expression was only possible with the k-repressor protein overproducer recA _ strain JM 109. Apparently the ep138 is toxic to the bacterial cells, perhaps, due to its proposed DNA-binding capacity (Roubal et al., 198 1) . A similar result was obtained with the expression of ICP8 of HSVl (Pearson et al., 1985) , which seems to have the same DNA-binding function and shares homologies to the protein sequence of ep 138.
(c) Computer-predicted localization of antigenic sites
In the ELISA the presence of antigenic sites is important and not the entire protein. Since the expression of large parts of ep138 is diflicult and inefficient, we decided to express only small antigenic peptides from ep138. Antigenic sites are often assumed to be in hydrophilic areas. The examination of hydrophilicity plots, however, did not allow the identification of appropriate sites for a promising sub-genomic expression cloning. Based on the assumption that antigenic sites are mainly located within hydrophilic /?-turns, we used a computer program, which superimposes the data for hydrophilicity (Hopp and Woods, 1981) upon the secondary structures predicted from the algorithms of Chou and Fasman (1974a,b) and Argos et al. (1978) (Fig. 4) . A similar program was successfully used for predictions of antigenic sites in gpB from HSVl (Cohen et al., 1984 ). Our program was tested for its validity with the polio virus VP 1, where the antigenic sites were mapped by synthetic peptides or monoclo-20 mM Tris HCI, pH 9.0, 0.01 Y0 NaN, and 1 mM phenylmethyl-sulfonyl fluoride) and incubated with 5 ~1 each of the NPC serum pool (preadsorbed with a protein extract from EBV-negative BJA cells). Immune complexes were bound to protein Asepharose, washed, eluted by boiling and fractionated by SDS-12"; PAGE. The gel was dried and exposed to a X-ray film. pUC924 contains the 2.6-kb fragment from the BglII site to the third XhoI site, the translational stop codon from ep138 should be used and the resulting non-fusion protein has a size of about 80 kDa. The plasmid pMF924 was constructed from pEA305 (Amann et al., 1983 ) and the same EglII-XhoI fragment as in pUC924. pEA305 has a tat promoter followed by the N-terminal part of the cI857-coded i, repressor, hence the resulting fusion protein is 17 kDa larger than from pUC924. The plasmid pUC635 has an insert corresponding to aa 108 up to aa 1127, the aa immediately before the stop codon ofep138. The 3.05kbXho1 fragment was inserted into the Sal1 site of pUC8 and the reading frame of the pUC-encoded IacZa fits with the ep138 ORF at the 5' and the 3' end. The resulting expression product is a fusion protein with 11 aa at the N-terminus and 1 I kDa of the IucZa. 307 nal antibodies (Jameson et al., 1984) . The computer predictions agree very well with the recently determined X-ray crystallographic data (Hogle et al., 1985) . This approach suggested the presence of two major potential antigenic epitopes (Fig. 4) one located around aa 520 (FR.IV) and the other close to the C-terminus of ep 138 (FR.VII).
(d) Subcloning and expression as j?Gal fusion proteins of DNA fragments encoding segments of ep138
To test the computer-aided localization, we examined segments of ep138 for antigenicity. Since most eukaryotic protein segments are degraded immediately after synthesis in bacteria, fusion proteins with the large bacterial /?Gal were constructed to protect the ep138 protein segments from proteolysis. The DNA fragments corresponding to the protein segments indicated in Fig. 4 were subcloned from the BarnHI-A fragment and pUC635 and inserted at the 3' end of the ZucZ gene of the pUR-vectors (Ruther and Mtiller-Hill, 1983). Western blot, using pooled human sera from NPC patients, allows the identification of antigenic ep138 segments (Fig. 5, right panel) . As predicted by our computer program, only the fusion proteins from clones pUR600 and pUR540 carrying FR.IV and FR.VII, respectively, react as EBV-specific antigens.
(e) Expression of the subfragments in pUC plasmid vectors
Due to the presence of antibodies in human sera specific for bacterial proteins, the use of BGal fusion proteins in ELISA may give erroneous results. Therefore, we tested whether the pUC clones used for the construction of the pUR plasmids (see legend frame with the pUC-encoded 1ucZsl at their 5' and 3' ends. Therefore the expression products are fusion proteins with a small 1 1-kDa flGa1 fragment at the C-terminus. Only the plasmid pUCP600, carrying the FR.IV-fragment (Fig. 4) , expresses an additional polypeptide of about 32 kDa resulting from transcription and translation of the 600-bp of FR.IV (21 kDa) and the 1acZcr (11 kDa) (Fig. 7, pUCP600 lanes, PA gel of the pUC constructs with FR.I,II,III,V,VI and VII not shown). In an immunoblot with the NPC serum pool this protein gives a stronger signal than the corresponding pUR clone, suggesting that the epitope in the large fusion product is partially hidden by the large /IGal. The instability of the translation products from pUC vectors carrying the other DNA fragments of the ep138 coding region is not too surprising since the products are small protein segments which might not fold such that they are protected from proteolytic degradation.
When the E. coli strain JM83 was transformed with the pUC-derived plasmids, all transformed colonies on agar plates containing XGal and Ap appeared light blue. Strain JM83 does not overproduce the lac repressor and needs the N-terminal part of the fiGa encoded by the pUC plasmid for the a-complementation of its partially deleted genomic 1acZ gene. The light blue color indicates that the ORF of the pUCencoded 1ucZ from the initiation codon through the inserted fragment is transcribed and translated. This finding suggests that all subfragments are expressed, but degraded immediately after synthesis. (Fig. 4 ) the fragments FRIV in pUR600 and FR.VII in pUR540 encode protein segments which were recognized by the human immune system. The HgiAI-PsrI fragment (FR.1, Figs. 1 + 4) was cloned from BarnHI-A into pUC9 to yield pUCHP, isolated from this plasmid as EcoRI-Hind111 fragment and inserted into pINIIIA1. With this procedure a second BanrHI site (besides the one originated from pUC9) was generated next to the Hind111 site. From a resulting clone the FR.1 was excised with BumHI and inserted into pUR288 to yield pURHP. pUR400 carrying FR.11 was obtained from pUC635 digested with PsrI, religation (pUCP400) and insertion of FRII as BumHI-Hind111 fragment into pUR288. The constructs pUR380 (FRIII), pUR600 (FRIV), pUR210 (FR.V), pUR750 (FR.VI) and pUR540 (FR.VII) were achieved by insertion of PstI fragments of pUC635 into pUC8, isolation of the EBV DNA sequences as BumHI-Hind111 fragments and ligation with pUR288. (1) Scheme of the cloning procedures. Using a SstI site which is located 25 bp from the 5' PstI site (Fig. 1) (f) Combination of the two antigenic sites and insertion of an oligodeoxynucleotide encoding oligoarginine DNA fragments FR.IV and FR.VII were combined in frame on one plasmid to obtain an ORF encoding both antigenic regions found in ep138. To prevent translation of vector-encoded sequences, a synthetic oligodnt coding for two translational stop codons was inserted at the 3' end of the ORF. The oligodnt further codes for five arginine residues 5' of the stop codons.
The resulting construct (pUCARG1140) codes for a protein consisting of the two antigenic epitopes with five arginine residues at the C-terminus. The protein segment encoded by FR.VII, which was previously shown to be instable in the pUC expression, is now stabilized by the peptide encoded by FR.IV. The additional arginine residues may be useful for the purification following a procedure of Sassenfeld and Brewer (1984) . The sequence of the oligodnt and the construction scheme for pUCARG 1140 is given in Fig. 6 and the expression products of the various constructs leading to pUCARG1140 are shown in Fig. 7 . The combination of the two antigenic sites was necessary to cover the spectrum of antibodies directed against ep138, since the immunological reactions differ in the various patients (Fig. 8) pool prepared from many sera of NPC patients did not detect additional antigenic sites (Fig. 5 ). These data imply that both antigenic sites are necessary and sufficient to obtain the desired specificity in the ELISA usable for diagnostic purpose.
A partially purified preparation of the pUCARG-1140-encoded protein was used to immunize rabbits. reacts specifically with the rabbit antiserum, which is further proof for the correct expression of this protein.
Preliminary experiments indicate the value of the pUCARG1140-encoded protein as antigen in the diagnostic of EBV-related diseases of NPC (in preparation).
The antigen encoded by pUCARGll40 is only a first step in generating a complete set of proteins covering all necessary antigens for EBV diagnosis.
Beside ep138, we have expressed another early protein, a VCA protein, a nuclear antigen and the major membrane protein of EBV (in preparation).
